Mark Cuban’s Cost Plus Drugs vision for custom rare disease medicines continues to expand internationally through shipments of DNA-like molecules designed for individual patient mutations and other rare conditions. The development reflects growing focus on manufacturing and supply pathways for off-the-shelf and patient-specific rare disease therapeutics, with the program positioning itself to serve patients beyond the US.